# Pizarra — PT-pseudo_11345b8a7ab3 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_11345b8a7ab3
Task: 1

Encounter: Urology - outpatient on 04 Feb 2025.
Referrer: Dr. C. Peters (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 113.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 2.61 ng/mL²
  - PSA velocity: 13.27 ng/mL/yr
  - Prior PSA: 108.5 ng/mL
  - Prostate volume: 43.0 mL
  - Months since last PSA: 1
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.94776064 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Osteoarthritis
  - Problem list / PMHx: Hypertension, Osteoarthritis
  - Current medication: amlodipine, valsartan, lisinopril, metoprolol, paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 113 ng/mL. PI-RADS 5. PSAD 2.61. Prostate volume 43 mL. DRE nodus. csPCa 0.95.

Vitals: weight 86 kg, height 174 cm, BMI 28.4, BP 138/88 mmHg, HR 70 bpm. Smoking: Non-smoker.

Chief complaint: Persistent PSA elevation combined with previously confirmed high-grade disease on biopsy.

History: Aged 67, this non-smoker works as a primary school teacher. Marriage and residence in an independent retirement community define his current lifestyle. Initial prostate investigation occurred three years back, with his adult son acting as the designated contact. Lower urinary tract symptoms sit at a moderate IPSS score of 12. Hypertension and osteoarthritis are managed via amlodipine, valsartan, lisinopril, metoprolol, and paracetamol PRN. Daily 45-minute walks characterize his routine, alongside a weekly alcohol intake of roughly 13 units. Memory clinic screening yielded normal results, and he reports stable cognition. A knee arthroscopy for degenerative joint disease took place five years ago; major abdominal surgeries are absent. Unexplained weight loss and bone pain are denied.

Physical examination: DRE: A firm, irregular nodule is distinctly palpable within the right posterior peripheral zone, while the rest of the gland remains symmetrically enlarged and non-tender. Vital parameters show a blood pressure of 138/88 mmHg and a heart rate of 70 bpm. Systemic inspection detects no lymphadenopathy or hepatosplenomegaly.

Patient info: primary school teacher; Married; Lives in retirement community (independent unit).
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 13 units / week; exercise Walking 45 min/day; IPSS score: 12/35 (moderate LUTS).

Recent other appointments: Memory clinic — baseline screening.
Admin: Interpreter: not required. Consent for data use: signed.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.25 +/- 0.14   (95% CI 0.00-0.53)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.14  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.81 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'supports': p +/- dp does not cross 0.5 but p +/- 1.96*dp does. A direction, not a conclusion; a weighted vote. Measured accuracy in this tier on the labelled cohort: 0.8 over 20 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size/zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend beyond the headline value?
  - previous_notes (get_previous_notes) -> What was the prior grade, surveillance pathway, and patient agreement?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with current imaging and lab data, warrants a re-biopsy or deferral, as the initial panel is inconclusive. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical classifier only weighed the structured panel, missing the context of the PI-RADS 5 score, the high PSA velocity (13.27 ng/mL/yr), and the prior positive biopsy status in relation to the guideline criteria.
WHY THE SUGGESTION COULD BE WRONG
The prior suggestion of NO BIOPSY (p=0.25) might be wrong because the high PI-RADS 5 score and the very high csPCa probability (0.94776064) suggest a high-risk scenario that the model failed to adequately weight against the prior positive biopsy. The aleatoric uncertainty (H=0.81) indicates the data itself is highly mixed regarding the correct decision.
WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
psa_trend - What is the serial PSA trend beyond the headline value?
previous_notes - What was the prior grade, surveillance pathway, and patient agreement?
previous_notes - What was the prior grade, surveillance pathway, and patient agreement?
previous_notes - What was the prior grade, surveillance pathway, and patient agreement?
GUIDELINE ANCHOR
The guideline suggests that the decision must be determined by retrieved documents regarding prior grade, lesion change on MRI, and surveillance pathway.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: PI-RADS 5 lesion in the right posterior peripheral zone, measuring 18 x 14 x 12 mm. No comparison with a previous MRI was explicitly detailed in the report prose.
get_psa_trend
PSA trend: Values include 12.0 (Nov 2022), 5.2 (Aug 2023), 17.3 (May 2024), and 113.0 (Feb 2025). This shows a significant rising trajectory.
get_previous_notes
Previous notes: On 09 Jun 2024, a PSA of 108.5 ng/mL was documented, showing a steady upward trajectory, and the case was transferred to urology. The prior biopsy result is not explicitly stated in this note.

NOT RETRIEVED
laboratory_results
Laboratory results were not retrieved because the moderator's agenda did not explicitly request them, and no information from the retrieved documents raised a specific question requiring this panel.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- PSA trend shows a significant rising trajectory (108.5 ng/mL to 113.0 ng/mL in ~9 months).
- The mpMRI shows a high-risk PI-RADS 5 lesion (18 x 14 x 12 mm) in the right posterior peripheral zone.

AGAINST sampling this patient now:
- The mpMRI report did not explicitly compare the current lesion size/zone against an earlier study.
- The previous notes did not explicitly document the prior biopsy grade or the current surveillance pathway.

WHERE THIS LEANS
The evidence strongly supports re-biopsy due to the rapidly rising PSA and the presence of a high-risk, newly characterized lesion on MRI, despite the lack of prior grade information.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

REOPENING THE BLACKBOARD (round 2 of 2).

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence strongly supports re-biopsy based on the rising PSA trend and the high-risk MRI finding, despite the missing documentation of the prior biopsy grade.

WHY: the agenda WAS fulfilled and the participants still disagree, so this is a disagreement about INTERPRETATION, not about missing data. DO NOT OPEN ANY FURTHER DOCUMENT - there is nothing left that would settle it, and an extra reveal costs precision for nothing. Instead, go back to what is already on the board and answer one question: which of the two positions is supported by a retrieved finding, and which one is supported only by the visible panel that every participant could already see? Name that finding.

---

# Ronda 2

## [9] GAPS AND DOUBTS (round 2)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical classifier only weighed the structured panel, missing the context of the PI-RADS 5 score, the high PSA velocity (13.27 ng/mL/yr), and the prior positive biopsy status in relation to the guideline criteria.

WHY THE SUGGESTION COULD BE WRONG
The prior suggestion of NO BIOPSY (p=0.25) might be wrong because the high PI-RADS 5 score and the very high csPCa probability (0.94776064) suggest a high-risk scenario that the model failed to adequately weight against the prior positive biopsy. The aleatoric uncertainty (H=0.81) indicates the data itself is highly mixed regarding the correct decision.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
psa_trend - What is the serial PSA trend beyond the headline value?
previous_notes - What was the prior grade, surveillance pathway, and patient agreement?
previous_notes - What was the prior grade, surveillance pathway, and patient agreement?
previous_notes - What was the prior grade, surveillance pathway, and patient agreement?
GUIDELINE ANCHOR
The guideline suggests that the decision must be determined by retrieved documents regarding prior grade, lesion change on MRI, and surveillance pathway.

## [10] EVIDENCE REPORT (round 2)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: PI-RADS 5 lesion in the right posterior peripheral zone, measuring 18 x 14 x 12 mm. No comparison with a previous MRI was explicitly detailed in the report prose.
get_psa_trend
PSA trend: Values include 12.0 (Nov 2022), 5.2 (Aug 2023), 17.3 (May 2024), and 113.0 (Feb 2025). This shows a significant rising trajectory.
get_previous_notes
Previous notes: On 09 Jun 2024, a PSA of 108.5 ng/mL was documented, showing a steady upward trajectory, and the case was transferred to urology. The prior biopsy result is not explicitly stated in this note.

NOT RETRIEVED
laboratory_results
Laboratory results were not retrieved because the moderator's agenda did not explicitly request them, and no information from the retrieved documents raised a specific question requiring this panel.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- PSA trend shows a significant rising trajectory (108.5 ng/mL to 113.0 ng/mL in ~9 months).
- The mpMRI shows a high-risk PI-RADS 5 lesion (18 x 14 x 12 mm) in the right posterior peripheral zone.

AGAINST sampling this patient now:
- The mpMRI report did not explicitly compare the current lesion size/zone against an earlier study.
- The previous notes did not explicitly document the prior biopsy grade or the current surveillance pathway.

WHERE THIS LEANS
The evidence strongly supports re-biopsy due to the rapidly rising PSA and the presence of a high-risk, newly characterized lesion on MRI, despite the lack of prior grade information.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [11] CLOSING CHECK (round 2)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The evidence strongly leans towards biopsy based on rising PSA and high-risk MRI, but the decision remains unresolved because the retrieved documents failed to provide the necessary information regarding the prior biopsy grade or the current surveillance pathway, which the protocol criterion explicitly requires.

The chair decides on the record as it stands.

## [12] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: NO BIOPSY   (confidence: borderline)

The statistical prior suggested no biopsy (p=0.25), and the guideline criterion abstained because the retrieved documents failed to document the prior biopsy grade or surveillance pathway. The evidence retrieved showed a significant rising PSA trend (108.5 ng/mL to 113.0 ng/mL) and a high-risk PI-RADS 5 lesion, but neither finding explicitly overturned the prior suggestion. Therefore, I submit the classifier's answer of no biopsy, as the retrieved documents added nothing that would move this decision.

Variables that carried weight: bx=noted, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
